Press-release for stocks for ATHA

Prices are updated after-hours

symbols : ATHA

save search

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| -17.44% | O: -5.43% H: 1.84% C: -15.57%
pharma medical

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| -13.06% | O: 4.9% H: 6.03% C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical

Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors
Published: 2024-04-04 (Crawled : 04:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -3.6% | O: 1.18% H: 0.0% C: 0.0%
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| -11.25% | O: 5.42% H: 5.18% C: -1.19%

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-03 (Crawled : 11:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| -14.11% | O: -3.23% H: 0.0% C: 0.0%
pharma presentation meeting

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| -48.67% | O: 0.0% H: 1.45% C: -13.73%
fosgonimeton pharma conference alzheimer’s international preclinical parkinson’s potential

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Published: 2024-02-22 (Crawled : 21:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| -45.8% | O: 1.78% H: 1.0% C: -1.75%
pharma business year pipeline financial results

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| -32.81% | O: 1.89% H: 3.72% C: 2.79%
ath-1105 pharma publication sclerosis potential

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| -25.78% | O: -0.35% H: 13.29% C: 10.84%
pharma business update pipeline

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Published: 2024-01-03 (Crawled : 12:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| -26.3% | O: -1.73% H: 12.32% C: 6.69%
fosgonimeton pharma disease alzheimer’s lift-ad trial

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Published: 2023-12-12 (Crawled : 12:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| 3.9% | O: -2.93% H: 10.55% C: 6.53%
fosgonimeton pharma disease parkinson's treatment dementia trial results

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
Published: 2023-11-29 (Crawled : 12:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| 47.92% | O: 0.69% H: 2.76% C: -3.1%
pharma conference

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| 39.22% | O: -1.96% H: 0.07% C: -4.0%
pharma disease symposium presentation international

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
Published: 2023-11-15 (Crawled : 13:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| 40.13% | O: 1.97% H: 6.77% C: 2.58%
pharma disease alzheimer’s preclinical in vitro

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| 53.24% | O: 7.91% H: 0.0% C: -1.33%
pharma business pipeline financial results

Athira Pharma to Participate in Jefferies London Healthcare Conference
Published: 2023-11-08 (Crawled : 12:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| 41.06% | O: 3.31% H: 0.0% C: -3.85%
pharma conference

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Published: 2023-10-05 (Crawled : 20:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| 18.33% | O: -0.56% H: 6.15% C: 5.59%
ath-1105 pharma sclerosis preclinical potential

Athira Pharma to Participate in Upcoming October Conferences
Published: 2023-09-28 (Crawled : 11:00) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K

Health Technology

| 12.11% | O: -0.53% H: 6.35% C: 5.82%
pharma